Weight-Loss Medications Influence Grocery Spending Patterns in the UK
The rise in popularity of weight-loss medications such as Wegovy and Mounjaro has led to significant changes in grocery spending among users in the UK. Over two million people in the UK are now using these medications, which work by mimicking the hormone GLP-1 to help regulate appetite. According to a study conducted by Worldpanel by Numerator, households with at least one GLP-1 user reported an average decrease of £418 in grocery spending in the year after beginning their medication, contributing to an estimated national reduction of £780 million in grocery expenditures.
This trend aligns with findings from a peer-reviewed study from Cornell University, which indicated that US households with a member using weight-loss drugs spent 5% less on groceries within six months of starting treatment, a figure that increased to 8% among higher-income families. The Worldpanel study also highlighted that users tended to cut back on calorie-dense and processed foods, leading to decreased spending on items like chocolate, pastries, and soft drinks while increasing purchases of healthier options such as fruits and protein-rich foods.
Interestingly, the study noted that users also began buying more products like chewing gum, mouthwash, and hair dye, which are intended to address common side effects of GLP-1 medications, such as bad breath and hair thinning. Nishita Pattni, a senior consultant at Worldpanel, emphasized that the changes in spending are not merely about reducing expenses but represent a broader shift in consumer behavior.
Furthermore, the research revealed that nearly two-thirds of surveyed users reported trying to reduce their dining out expenses since starting their medications, with a significant decline in spending at fast-food outlets and coffee shops. The Cornell study corroborated these findings, noting an 8% drop in spending at such establishments.
Despite these potential savings, the cost of weight-loss medications remains a concern for many users, as most pay out of pocket, with monthly prescriptions exceeding £300. A survey conducted by Zava found that the primary reason for discontinuing medication was financial strain. Additionally, the Health Foundation pointed out that affluent regions in the UK have higher prescription rates despite lower obesity levels, raising questions about access and equity in treatment.




